Double Bond aims on adaptive design for SI-053 Phase I

Double Bond Pharmaceutical (DBP) has signed a service contract with Cytel Inc, a leading provider of clinical research services and software, to develop an adaptive model-based study design for upcoming Phase I clinical trial for SI-053. “In our planned Phase I dose-escalation study we aim on using an adaptive model-based design to help identify the maximum tolerated dose (MTD) of SI-053, - says Dr Breezy Lindqvist, CMO of DBP. - This is considered to be much more effective than the traditional 3+3 model and is a crucial step in the clinical development of SI-053, as it also decides the